Bitwise Crypto Industry Innovators ETF vs Moderna, Inc. — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $23.52, while Moderna, Inc. trades at $67.44 (market cap $26.76B). The key difference: Moderna, Inc. is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| BITQ | MRNA | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $81.80 |
52-Week Low | $16.74 | $22.36 |
Market Cap | — | $26.76B |
Enterprise Value | — | $22.85B |
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $23.18, down 3.13% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators show neutral conditions. Support levels cluster around $23-24 while resistance sits at $25-26. Recent news highlights investor rotation away from crypto-related ETFs as Bitcoin prices decline, creating headwinds for BITQ's performance.
The outlook remains cautious given the bearish technical setup and sector-specific challenges. Investment opportunity exists for contrarian investors betting on crypto market recovery, but risks include continued ETF outflows and regulatory uncertainty. The stock's performance remains tightly correlated with broader cryptocurrency sentiment rather than standalone fundamentals.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Trailing returns across standard periods
Latest headlines on both assets
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →